- Home
- RVPH vs AIXI Comparison
RVPH vs AIXI Comparison
Compare RVPH & AIXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPH
- AIXI
- Stock Information
- Founded
- RVPH 2006
- AIXI 2001
- Country
- RVPH United States
- AIXI China
- Employees
- RVPH N/A
- AIXI N/A
- Industry
- RVPH Biotechnology: Pharmaceutical Preparations
- AIXI Computer Software: Prepackaged Software
- Sector
- RVPH Health Care
- AIXI Technology
- Exchange
- RVPH Nasdaq
- AIXI Nasdaq
- Market Cap
- RVPH 32.8M
- AIXI 31.2M
- IPO Year
- RVPH N/A
- AIXI 2023
- Fundamental
- Price
- RVPH $0.42
- AIXI $2.14
- Analyst Decision
- RVPH Strong Buy
- AIXI
- Analyst Count
- RVPH 5
- AIXI 0
- Target Price
- RVPH $9.00
- AIXI N/A
- AVG Volume (30 Days)
- RVPH 3.4M
- AIXI 138.1K
- Earning Date
- RVPH 08-13-2025
- AIXI 05-15-2025
- Dividend Yield
- RVPH N/A
- AIXI N/A
- EPS Growth
- RVPH N/A
- AIXI N/A
- EPS
- RVPH N/A
- AIXI N/A
- Revenue
- RVPH N/A
- AIXI $70,314,315.00
- Revenue This Year
- RVPH N/A
- AIXI $26.84
- Revenue Next Year
- RVPH N/A
- AIXI N/A
- P/E Ratio
- RVPH N/A
- AIXI N/A
- Revenue Growth
- RVPH N/A
- AIXI 18.84
- 52 Week Low
- RVPH $0.30
- AIXI $2.06
- 52 Week High
- RVPH $4.28
- AIXI $8.31
- Technical
- Relative Strength Index (RSI)
- RVPH 33.44
- AIXI 41.81
- Support Level
- RVPH $0.35
- AIXI $2.20
- Resistance Level
- RVPH $0.83
- AIXI $2.60
- Average True Range (ATR)
- RVPH 0.06
- AIXI 0.31
- MACD
- RVPH -0.01
- AIXI -0.01
- Stochastic Oscillator
- RVPH 17.36
- AIXI 23.33
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
About AIXI XIAO-I Corporation
XIAO-I Corp is an AI industrialization company focusing on the AI Cognitive Intelligence platform. The platform combines six core technologies including Natural Language Processing, Speech Processing, Computer Vision, Machine Learning, Affective Computing, Data Intelligence, and Hyper- automation. Based on the platform, The company developed products and solutions in the fields of Al+ Contact Center, Al+ Finance, Al+ City Public Service, Al+ Architecture, Al+ Metaverse, Al+ Manufacturing, and Al+ Healthcare. It generates revenue from the sale of software products and services, M&S services, and the sale of cloud platform products.